No­vo Nordisk grabs a $486M buy­out op­tion on an an­ti-apoC3 an­ti­body for its car­dio R&D group

A cou­ple of months af­ter re­struc­tur­ing its R&D op­er­a­tions, No­vo Nordisk has whipped up a $486 op­tion deal to buy out Stat­en Biotech­nol­o­gy — if their lead drug comes through in clin­i­cal tri­als. 

The main at­trac­tion at the Nether­lands-based Stat­en is an an­ti-apoC3 an­ti­body — dubbed  STT-5058 — which has a shot at re­duc­ing triglyc­erides and rem­nant lipopro­teins, well known tar­gets in the high-risk car­dio field.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER